Genetic alterations define different molecular subclasses of hepatocellular adenoma (HCA) linked with risk factors, histology and clinical behavior. Recently, Argininosuccinate Synthase 1 (ASS1), a major periportal protein, was proposed as a marker of HCA with a high risk of hemorrhage. We aimed to assess the significance of ASS1 expression through the scope of the HCA molecular classification. ASS1 expression was evaluated using RNAseq, quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and Immunohistochemistry. ASS1 and glioma-associated oncogene 1 (GLI1) expression were analyzed in vitro after modulation of GLI1 expression. Using RNAseq in 27 HCA and five nontumor liver samples, ASS1 expression was highly correlated with GLI1 expression (P<0.0001, R50.75). In the overall series of 408 HCA, ASS1 overexpression was significantly associated with sonic hedgehog HCA (shHCA) compared to other molecular subgroups (P<0.0001), suggesting that sonic hedgehog signaling controls ASS1 expression. GLI1 expression silencing by siRNA induced a downregulation of ASS1 in PLC/PFR5 and SNU878 cell lines. In 390 HCA, we showed that ASS1 expression belonged to the periportal expression program that was maintained in shHCA but down-regulated in all the other HCA subtypes. In contrast, HCA with b-catenin activation showed an activation of a perivenous program. Despite the significant association between GLI1 and ASS1 expression, ASS1 mRNA expression was not associated with specific clinical features. At the protein level using immunohistochemistry, prostaglandin D synthase (PTGDS) was strongly and specifically overexpressed in shHCA. Conclusion: ASS1 is associated with sonic hedgehog activation as part of a periportal program expressed in shHCA, a molecular subgroup defined by INHBE-GLI1 gene fusion. (HEPATOLOGY 2018; 68:964-976).
H epatocellular adenomas (HCA) are rare benign liver tumors usually developed under estrogen exposition in young women who have taken oral contraception. (1) HCA diagnosis is sometimes difficult among other benign liver tumors, and well-differentiated hepatocellular carcinoma (HCC) and patient management may also be difficult due to the low rate of complications, mainly tumor bleeding and malignant transformation. (2) Molecular classification has help to reappraise the mechanisms of benign liver tumorigenesis. (3) We identified 8 molecular HCA subgroups that are related with specific clinical behavior including risk factors, diagnosis and also prognosis. (3, 4) The different molecular subtypes are defined by bona fide genetic defects observed in tumor hepatocytes. (5) The first subgroup (HNF1A inactivated HCA, HHCA, 34%) is defined by biallelic inactivating mutations of the transcription factor HNF1A; they are characterized by a marked steatosis in tumor hepatocytes and the loss of expression of L-FABP protein, whose expression is controlled by HNF1A. (6, 7) Activation of JAK/STAT3 pathway due to various activating gene mutations in the pathway (IL6ST, STAT3, FRK, GNAS, JAK1) defined the second subgroup of HCA, namely inflammatory HCA (IHCA, 34%). (8) (9) (10) (11) At pathological reviewing, IHCA are characterized by inflammatory infiltrates, sinusoidal dilatation, dystrophic arteries and CRP and SAA overexpression in the tumor. The third group defined by b-catenin (cadherin-associated protein) beta 1 (CTNNB1) mutations in exon 3 (b ex3 HCA, 7%), is the most frequent subtype in male and associated with a higher risk of malignant transformation. (12) At histology, b ex3 HCA harbored frequently cholestasis, cytological atypia and could be detected using glutamine synthase (GS) overexpression and b-catenin translocation in the nucleus. In contrast, HCA with CTNNB1 mutations in exon 7 and 8 (b ex7, 8 HCA, 3%) are not associated with malignant transformation and are currently difficult to identify using immunohistochemistry. (13) Interestingly, half of CTNNB1 mutated HCA in exon 3 (b ex3 IHCA, 6%) and in exon 7 or 8 (b ex7,8 IHCA, 4%) have also an inflammatory phenotype. Recently, a new subgroup of HCA (sonic hedgehog HCA [shHCA], 4%) has been identified and defined by a glioma-associated oncogene 1 (GLI1) overexpression due to a deletion leading to a fusion between INHBE and GLI1. (14) These fusions activate constitutively the sonic hedgehog pathway into tumor hepatocytes. Sonic hedgehog HCA have been associated with a high rate of histological but also clinical symptomatic bleeding. (14) Finally, only 7% of HCA remains unclassified (UHCA).
Recently, Argininosuccinate Synthase 1 (ASS1) has been identified using proteomic analysis as overexpressed in a subgroup of HCA mainly composed of UHCA. It was proposed as a marker of a new subclass of adenoma (named ASS11 HCA) linked with the risk of hemorrhage and proposed to stratify the risk of bleeding and to guide treatment. (15) We hypothesize that ASS1 could be a surrogate marker of shHCA and be induced by sonic hedgehog pathway activation. Moreover, since ASS1 is a well-known periportal marker in the liver lobule, (16, 17) we analyzed a large number of HCA to search for alterations of liver zonation program related to various molecular subgroups.
Materials and Methods

PATIENT SELECTION
This study included 408 HCA from 318 patients. Patients and tumor features were already included in a previous study. (14) Briefly, among the 408 HCA, 7 % were borderline lesions and 3% over malignant transformation in HCC, whereas the remaining cases were typical HCA. Eighty-four % of the patients were female, with a median age of 38 years old; 88% of them taking oral contraception. Fifty-five % of the tumors harbored histological hemorrhage and 15% of the patients have symptomatic bleeding at 
mRNA EXPRESSION ANALYSIS
Gene expression of 27 HCA and five nontumor liver tissue samples were analyzed by RNA-sequencing as previously described. (14) This panel of 27 adenomas includes HCA from various molecular subgroups and was enriched with sonic hedgehog HCA (n59).
Recently, analysis of gene expression involved in liver zonation in a mouse model showed that ASS1 and ASL were key proteins involved in the periportal program of liver zonation. (16, 17) We hypothesized that GLI1 activation in shHCA could induce an alteration of the zonation program. In addition to ASS1 and ASL, we selected in the literature five other genes known to be expressed in periportal region (HAL, SDS, GNMT, GLS2 and PCK1) and severn genes expressed in perivenous region (CYP2E1, CYP1A2, RHBG, SLC22A12, GLUL, LGR5, AXIN2). (18) (19) (20) (21) (22) (23) We assessed gene expression by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using Fluidigm technology and Taqman probes. (13, 24) Taqman probes used to assess ASS1 and ASL were Hs01597989_g1 and Hs00902699_m1 respectively. Other Taqman probes were Hs00157887_m1 (HAL), Hs01566038_m1 (SDS), Hs00219089_m1 (GNMT), Hs00998725_g1 (GLS2), Hs00159918_m1 (PCK1), Hs00374213_m1 (GLUL), Hs00173664_m1 (LGR5), Hs00610344_m1 (AXIN2), Hs00559368_m1 (CYP2E1), Hs00167927_m1 (CYP1A2), Hs01085 479_g1 (RHBG) and Hs01030727_m1 (SLC22A12). Data were normalized with the RNA ribosomal 18S as the calibrator and with the 2-delta delta CT method with the mean of the corresponding gene expression in normal liver tissues. Results were expressed as an nfold ratio compared to normal liver tissue.
IN CELLULO MODEL
A series of 32 hepatocellular cell lines including 30 HCC, 2 hepatoblastoma were purchased from different vendors or obtained from gifts as previously described (HepaRG was obtained from Fabien Zoulim, Inserm U1052). (25) Cell line identity was checked by exome sequencing, SMMC7721 and BEL7402 were excluded for HeLa contamination identified worldwide. (26) PLC/PFR5 and SNU878 were grown in Dulbecco's modified Eagle's medium (DMEM). Cells were maintained at 378C in a humidified incubator in 5% CO 2 . Culture media were supplemented with 10% fetal bovine serum and 100 U/mL penicillin/ streptomycin. We performed siRNA transfections, as previously described, (27) in six well-plates using the lipofectamine RNAiMax reagent (Invitrogen) with siRNA targeting GLI1 (NM_001160045.1, exon 8, ref taqman s5816), according to the manufacturer's protocol. Block-iT Alexa Fluor Red Fluorescent Oligo siRNA (Invitrogen) was used as a double-stranded RNA negative control. 10 nM of GLI1 siRNA or a IHCA) and 4 focal nodular hyperplasia. All stainings were performed on tumor sections. After dewaxing and rehydratation, sections were placed into a boiling target retrieval solution (DiaPath Citrate Buffer pH 6) for 40 minutes and then left to cool down for 20 minutes. Slides were further processed on an automated immunostainer (Dako Autostainer). Endogenous peroxidase was blocked with H 2 O 2 (Dako, 10 minutes) and nonspecific background staining with goat serum (20 minutes) and Avidin/Biotin blocking reagent (Vector Labs). Next, sections were incubated with a primary anti-ASS1 (HPA020896, Sigma-Aldrich, dilution 1/ 500) antibody for 1 hour at room temperature and washed with phosphate-buffered saline solution. After signal amplification with the Immpress Rabbit Polymer and staining with 3-diaminobenzidine (Dako) as chromogen, the slides were counterstained with Mayer's haematoxylin, dehydrated and mounting. Prostaglandin D synthase (PTGDS) immunostaining was performed (HPA004938 Anti-PTGDS, Sigma Aldrich, dilution 1:25) including a retrieval step (40 minutes, pH 6 Citrate buffer at 988C). SAA, GS and LFAPB immunostaining was performed as previously described. (6, 7) Immunohistochemical staining of ASS1 and PTGDS were assessed by VP and JC as follows:
1. Percentage of stained cells. 2. Staining intensity using a semi quantitative score (1: weak, 2: moderate and 3: strong).
STATISTICAL ANALYSIS
Statistical analysis and data visualization were performed using both R software version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org) and PRISM software (GraphPad Software, Inc., La Jolla, CA). Continuous variables were compared using either parametric test (t-test) or nonparametric text (Mann-Whitney test to compare two groups and Kruskall-Wallis test to compare more than two groups). Correlation between continuous data was performed using Pearson test. Categorical variables were compared using the Fisher exact test. A P value < 0.05 was considered as significant. Unsupervised clustering analysis was performed using the expression levels of 14 genes, including seven periportal and seven perivenous genes, analyzed by qPCR. Clusters and samples were ordered based on the hierarchical clustering using Ward's linkage method and Euclidean's correlation as distance metric. Principal component analysis (PCA) using the first three components was also generated.
Results
ASS1 OVEREXPRESSION IN SONIC HEDGEHOG HCA
To test if ASS1 expression could be related to a specific molecular subgroup of HCA we first analyzed ASS1 mRNA expression in a series of 27 HCA (including 9 shHCA with INHBE-GLI1 fusion, 3 HHCA, 9 IHCA, 4 b ex3 HCA, 2 b ex3 IHCA) and five nontumor liver samples analyzed by RNA sequencing. ASS1 was highly expressed in normal livers (median FPKM 5 170). We identified an ASS1 overexpression in all nine shHCA whereas the other molecular subgroups of HCA demonstrated a lower expression of ASS1 when compared with the nontumor liver samples (Fig. 1A) . GLI1 expression, the hallmark of the shHCA, was significantly correlated with ASS1 expression (P<0.0001, R50.75, Pearson test, Fig. 1B) . Next, we aimed to validate the relationship between ASS1 expression and shHCA subgroup of HCA in a large series of 408 HCA using quantitative RT-PCR (see Table 1 for description of patients and tumors). We confirmed that ASS1 was overexpressed in shHCA compared to other molecular subgroups including UHCA (Fig. 1C , P < 0.0001, Kruskall Wallis Test).
A cohort of validation including 50 HCA confirmed the overexpression of ASS1 in shHCA (P < 0.0001, Kruskall Wallis Test) and the correlation between ASS1 and GLI1 expression (P <0.0001, R50.769, Pearson test) (Supplementary Figs. S1B and S1A).
We also tested ASL expression coding for argininosuccinate lyase involved like ASS1 in arginine metabolism. (15, 28) As expected the expression of ASS1, ASL and GLI1 were closely correlated and with ASL highly expressed in shHCA compared to other subtypes using both RNAseq and qRT-PCR (Fig. 1A-C) .
These data demonstrated that ASS1 was overexpressed in shHCA and not in other molecular subgroups including UHCA representing 8% in this series.
GLI1 REGULATES ASS1 IN CELLULO
The close correlation of ASS1 and GLI1 expression levels in HCA and because GLI1 is a transcription factor, suggested that GLI1 could control ASS1 expression. To test this hypothesis, we first assessed GLI1 expression by quantitative RT-PCR in 32 HCC cell lines ( Fig. 2A) . Then, we selected two HCC cell lines with a strong GLI1 expression levels, PLC/PFR5 and SNU878. We transfected these two cell lines with siRNA against GLI1 in order to downregulate GLI1 expression compared to a control fluorescent siRNA. We found that siRNA directed against GLI1 lead to a downregulation of the expression of both GLI1 and ASS1 assessed by quantitative RT-PCR compared to a control fluorescent siRNA in PLC/PFR5 (Fig. 2B) and SNU878 (Fig. 2C) , showing that GLI1 could control ASS1 expression in cellulo. 
ACTIVATION OF PERIPORTAL PROGRAM IN SONIC HEDGEHOG HCA
We assessed the expression of the five periportal genes and seven perivenous genes using qRT-PCR. Expression levels of a panel of periportal and perivenous genes separate accurately the different molecular subgroups of HCA using unsupervised analysis with 3D PCA (Fig. 3A) and unsupervised hierarchical clustering (Fig. 3B) . In addition to ASS1 and ASL, the five genes belonging to the periportal program were significantly overexpressed in shHCA compared to other molecular subgroups in 408 analyzed HCA (Fig.  4A) . Also, in agreement with the role of b-catenin in liver zonation, HCA with activation of b-catenin pathway due to canonical mutation of CTNNB1 mutation in exon 3 (b ex3 HCA and b ex3 IHCA) showed an overexpression of the perivenous genes and a downregulation of the periportal program (Fig. 4B) . In contrast, HHCA, IHCA and bex 7, 8 HCA did not exhibit an alteration of the liver zonation program. These data showed that GLI1 and b-catenin activation in HCA are associated with opposite periportal and perivenous concerted program, respectively.
ASS1 EXPRESSION AND IMMUNOHISTOCHEMISTRY AND CORRELATION WITH HISTOLOGICAL AND CLINICAL FEATURES
Then, we tested possible association between ASS1 and histological and symptomatic bleeding as proposed by Henriet et al. (15) In the whole series of HCA, ASS1 expression assessed by quantitative RT-PCR was not associated with histological hemorrhage (Supplementary Figs. S2A-S2D ).
As previously described, (15) ASS1 assessed by immunohistochemistry was overexpressed in shHCA but also in some other molecular subgroups suggesting that ASS1 IHC could lack of specificity to detect shHCA and also tumors with histological hemorrhage (Table 2 and Fig. 5A-C) . In nontumor liver, ASS1 expression was zonated and predominantly expressed in periportal area, validating our immunohistochemical technique (Fig. 5D) .
We previously described that PTGDS expression was strongly increased in shHCA (14) and we tested PTGDS immunohistochemistry in our series of tumors. All shHCA were diffusely positive in the tumor (from 40% to 100% of positivity in the tumor) compared to the nontumor liver, whereas HCA of other molecular subgroups were negative for PGTDS immunostaining (Table 2 and Fig. 5E-H) . We also observed a slight decrease of LFABP expression in shHCA compared to the surrounding normal liver (Fig. 5E ).
Discussion
Based on the analysis of a large numbers of HCA well characterized at the molecular levels, we pinpoint that ASS1 overexpression was increased in shHCA, whereas its expression was downregulated in other molecular subgroups including UHCA defined by molecular analysis. Consequently, ASS1 expression is increased in shHCA but not of all UHCA per se. (15) However, in term of diagnosis, ASS1 mRNA expression is only slightly increased in shHCA compared to other molecular subgroups. Expression of other genes assessed by quantitative RT-PCR was more accurate to detect shHCA such as GLI1 over-expression due to the INHBE-GLI1 fusion or PTGDS that is highly and specifically expressed in shHCA. (3) ASS1 was also overexpressed at the protein level in shHCA, however, additional studies are required to precise its diagnostic accuracy because aspecific positive immunostaining is observed in other molecular subtypes and in other benign liver tumors such as focal nodular hyperplasia. Specificity and sensitivity of this IHC marker remain to be carefully demonstrated before its translation in clinical practice and additional studies are warranted to assess the role of ASS1 immunohistochemistry to detect shHCA or assess the risk of HCA bleeding. Moreover, we previously described a huge expression of PTGDS in shHCA and we confirmed this overexpression of PTGDS by immunohistochemistry in shHCA and not in other molecular subgroups suggesting that PTGDS could be a good reliable surrogate marker of shHCA in routine. However, a multicentric validation in a larger set of tumors is required to compare ASS1 and PTGDS IHC for the diagnosis of shHCA. Moreover, we identified in some cases a slight decrease expression of LFABP in shHCA that need to (15) However, it is important to stress that in HCA, as in other type of hematological and solid tumors, molecular classification has been the gold standard to define new subclasses of adenomas, and it remains the backbone to identify new surrogate markers potentially useful in clinical practice. Denomination of each subgroups of HCA has been based on the mechanism at their origin (activation of inflammatory pathway for inflammatory HCA, inactivation of the transcription factor HNF1A for HNF1A inactivated HCA and mutations of b-catenin for bcatenin mutated HCA). (6, 8, 29) Thus, since ASS1 HCA (CHC4035T), (D) in nontumor liver (with a predominance of expression in periportal areas. (E) LFABP expression is slightly decreased in tumor compared to nontumor liver in a shHCA (CHC4032T) (F) SAA expression is negative both in the tumor (shHCA, CHC4032T) and nontumor liver (G) GS expression is focally expressed around vascular channels in the tumor (shHCA, CHC4032T) while it is restricted to centrolobular areas in nontumor liver (H) PTGDS is diffusely expressed in tumor hepatocytes in a shHCA without expression in nontumor liver (CHC4032T). Panel A to H: magnification 3100. T5 tumor, NT5 nontumor liver.
overexpression is a consequence of sonic hedgehog pathway activation due to INHBE-GLI1 fusions and because the specificity of ASS1 for the diagnosis of shHCA remains to be determined, the name of sonic hedgehog HCA should be kept in order to avoid confusion in denomination. (14) Interestingly, ASS1 was recently reported as a master gene of liver zonation activated in the periportal area of the lobule. (16, 17) We showed that ASS1 belong to a set of genes from a periportal program expressed in sonic hedgehog HCA and downregulated in other molecular subgroups (Fig. 6) . (18) This data confirmed in human tumors the role of sonic hedgehog pathway in zonation previously observed in mouse models. (30) (31) (32) (33) On the other hand, b-catenin exon 3 mutated HCA harbored a perivenous program because Wnt/ b-catenin was a key signaling pathway known to be involved in liver zonation and in the maintenance of a perivenous network of genes. (21, 22) Moreover, as ASL and ASS1 belong to the arginine synthesis pathway, these results suggested that arginine metabolism and urea cycle were mainly activated in periportal area and potentially controlled by sonic hedgehog pathway whereas glutamine synthesis were activated in perivenous area mainly by Wnt/b-catenin pathway (Fig. 6 ). (22, 23) In conclusion, ASS1 expression is associated with GLI1 activation in shHCA. Sonic hedgehog pathway controls the expression of a network of genes, 
